Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Genmab A/S - American Depositary Shares (NQ:GMAB)

31.81 -0.04 (-0.13%)
Streaming Delayed Price Updated: 2:48 PM EDT, Oct 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,407,862
Open 31.90
Bid (Size) 31.80 (3)
Ask (Size) 31.81 (4)
Prev. Close 31.85
Today's Range 31.59 - 31.95
52wk Range 17.23 - 33.63
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Electronic Arts Inc. (Nasdaq - EA), Merus N.V. (Nasdaq – MRUS), Berry Corporation (Nasdaq - BRY), Semler Scientific, Inc. (Nasdaq – SMLR)
From Brodsky & Smith LLC
Via GlobeNewswire
Why Genmab Stock Popped on Friday
Two pundits raised their price targets on the company. 
Via The Motley Fool

Performance

YTD
+51.5%
+51.5%
1 Month
+14.3%
+14.3%
3 Month
+45.5%
+45.5%
6 Month
+76.6%
+76.6%
1 Year
+34.5%
+34.5%

More News

Read More
Curious about the stocks that are showing activity after the closing bell on Friday?
Via Chartmill
Analyst Expectations For Genmab's Future
Via Benzinga
Why Genmab Stock Was Marching Higher Today
Via The Motley Fool
Merus N.V. Soars on $8 Billion Genmab Acquisition, Propelled by Oncology Pipeline Successes
Via MarketMinute
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Electronic Arts Inc. (Nasdaq – EA), Merus N.V. (Nasdaq – MRUS), Berry Corporation (Nasdaq – BRY), Semler Scientific, Inc. (Nasdaq – SMLR)
From Brodsky & Smith LLC
Via GlobeNewswire
Genmab Makes $8 Billion Bet On Merus With Potential Cancer Breakthrough
Via Benzinga
Genmab Strikes $8 Billion Deal To Acquire Cancer-Focused Merus
Via Investor's Business Daily
Topics Government
Genmab to Acquire Merus, Expanding Late-Stage Pipeline and Accelerating into a Wholly Owned Model
From Genmab A/S
Via Business Wire
Genmab Announces Updated Results from Phase 2 EPCORE® NHL-6 Study Evaluating Epcoritamab Monotherapy in the Outpatient Setting in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
From Genmab A/S
Via Business Wire
GENMAB A/S -SP ADR (NASDAQ:GMAB) Meets Peter Lynch's GARP Investment Criteria
Via Chartmill
GENMAB A/S -SP ADR (NASDAQ:GMAB): A High-Value Biotech Play with Strong Fundamentals
Via Chartmill
GENMAB A/S -SP ADR (NASDAQ:GMAB): An Affordable Growth Candidate in Biotechnology
Via Chartmill
Genmab Receives FDA Breakthrough Therapy Designation for Rinatabart Sesutecan (Rina-S®) in Advanced Endometrial Cancer (EC)
From Genmab A/S
Via Business Wire
Genmab/AbbVie Partnered Blood Cancer Combination Drug Cuts Risk Of Disease Progression By 79%
Via Benzinga
Genmab Announces Phase 3 EPCORE® FL-1 Clinical Trial Met Dual Primary Endpoints in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL)
From Genmab
Via Business Wire
GENMAB A/S -SP ADR (NASDAQ:GMAB) - A Biotech Stock With Strong Growth and Reasonable Valuation
Via Chartmill
Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for Autologous Stem Cell Transplantation (ASCT)
From Genmab
Via Business Wire
GENMAB A/S -SP ADR (NASDAQ:GMAB) – A Strong Candidate for GARP Investors
Via Chartmill
Why Genmab Stock Smashed It on Monday
Via The Motley Fool
Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 Trial
From Genmab A/S
Via Business Wire
GENMAB A/S -SP ADR (NASDAQ:GMAB) – A Strong Growth Stock Showing Technical Breakout Potential
Via Chartmill
Genmab to Highlight New Data Evaluating Late-Stage Oncology Portfolio at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
From Genmab A/S
Via Business Wire
GENMAB A/S -SP ADR (NASDAQ:GMAB) - A Strong Candidate for Affordable Growth Investors
Via Chartmill

Frequently Asked Questions

Is Genmab A/S - American Depositary Shares publicly traded?
Yes, Genmab A/S - American Depositary Shares is publicly traded.
What exchange does Genmab A/S - American Depositary Shares trade on?
Genmab A/S - American Depositary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Genmab A/S - American Depositary Shares?
The ticker symbol for Genmab A/S - American Depositary Shares is GMAB on the Nasdaq Stock Market
What is the current price of Genmab A/S - American Depositary Shares?
The current price of Genmab A/S - American Depositary Shares is 31.81
When was Genmab A/S - American Depositary Shares last traded?
The last trade of Genmab A/S - American Depositary Shares was at 10/10/25 02:48 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.